证券代码：603127 证券简称：昭衍新药 公告编号：2025-029 北京昭衍新药研究中心股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次利润分配方案经北京昭衍新药研究中心股份有限公司（以下简称"公司"）2025 年 6 月 18 日的2024年年度股东大会、2025 年第二次 A 股类别股东会议及 2025 年第二次 H 股类别 股东会议审议通过。 二、 分配方案 分派对象： ? 每股分配比例 A 股每股现金红利0.03元 ? 相关日期 | 股份类别 | 股权登记日 | | 最后交易日 | | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | --- | --- | | Ａ股 | 2025/8/13 | － | | 2025/8/14 | 2025/8/14 | | ? 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 除权（息）参考价格=（前收盘价格-现金红利）÷（1+流通股份变动比例） 由于公司本次进行差异化分红，上述公式 ...

Core Viewpoint - The legal opinion issued by Beijing Tianyuan Law Firm confirms that the differentiated dividend distribution plan of Beijing Zhaoyan New Drug Research Center Co., Ltd. complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [10]. Group 1: Differentiated Dividend Distribution - The differentiated dividend distribution is based on the company's 2024 annual profit distribution plan, which proposes a cash dividend of 0.3 yuan per 10 shares, calculated on the total share capital after excluding repurchased shares [8][9]. - The total net profit attributable to shareholders for the year 2024 is reported to be approximately 74.08 million yuan, with the proposed cash dividend representing 30.22% of this net profit [8][9]. - The company has confirmed that the total number of shares eligible for profit distribution is 746,174,300 shares after accounting for repurchased shares [8][9]. Group 2: Share Repurchase Plans - The company initiated a share repurchase plan in 2021, intending to use its own funds to repurchase shares for employee incentive plans, with a total repurchase amount between 4 million and 8 million yuan [4]. - In 2024, a new share repurchase plan was approved, allowing for a repurchase amount between 50 million and 100 million yuan, with a maximum repurchase price set at 150% of the average trading price over the previous 30 trading days [5][6]. - As of July 18, 2025, the company holds a total of 3,303,034 shares in its repurchase account, which does not participate in profit distribution [6][9]. Group 3: Legal Compliance and Due Diligence - The law firm conducted thorough due diligence to ensure that the differentiated dividend distribution adheres to the Company Law, Securities Law, and relevant regulatory guidelines [10]. - The legal opinion emphasizes that all provided documents and statements are accurate and complete, with no material omissions or misrepresentations [3][10]. - The firm confirms that the differentiated dividend distribution does not violate any laws or harm the interests of the company and its shareholders [10].

证券日报网讯 8月5日晚间，昭衍新药发布公告称，2024年年度权益分派方案为每股现金红利0.03元（含 税），股权登记日为2025年8月13日，除权（息）日及现金红利发放日均为2025年8月14日。 （文章来源：证券日报） ...

JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 北京昭衍新藥研究中心股份有限公司 馮宇霞 董事長 中 國 北 京，2025年8月5日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 大 鵬 先 生、孫雲霞女士、羅樨女士及顧靜良先生，及獨立非執行董事張帆先生、楊福全 ...

证券代码：603127 证券简称：昭衍新药 公告编号：2025-029 北京昭衍新药研究中心股份有限公司 2024年年度A 股权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.03元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/8/13 | － | 2025/8/14 | 2025/8/14 | 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经北京昭衍新药研究中心股份有限公司（以下简称"公司"）2025 年 6 月 18 日的2024年年度股东大会、2025 年第二次 A 股类别股东会议及 2025 年第二次 H 股类别 股东会议审议通过。 二、 分配方案 1. 发放年度：2024年年度 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简 ...

北京市天元律师事务所 关于北京昭衍新药研究中心股份有限公司 差异化分红事项的专项法律意见 北京市天元律师事务所 北京市西城区金融大街 35 号 国际企业大厦 A 座 509 单元 邮编：100033 1、本所仅根据本法律意见出具之日之前发生的事实、本所对该等事实的了 解及对本法律意见出具之日之前颁布施行的有关法律法规的理解发表法律意见。 致：北京昭衍新药研究中心股份有限公司 北京市天元律师事务所（以下简称"本所"）受北京昭衍新药研究中心股份 有限公司（以下简称"公司"或"上市公司"）的委托，根据《中华人民共和国 公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、《上海证券交易所上市公司自律监管指引第7号——回购股份》（以下简称 "《监管指引第7号》"）等相关法律、行政法规、部门规章及其他规范性文件（以 下合称"法律法规"）以及《北京昭衍新药研究中心股份有限公司章程》（以下简 称"《公司章程》"），就公司2024年度利润分配所涉及的差异化分红（以下简称"本 次差异化分红"）相关事项出具本法律意见。 为出具本法律意见之目的，本所根据相关法律法规的规定对涉及公司本次差 异化分 ...

Group 1 - The stock price of Zhaoyan New Drug as of August 4, 2025, is 31.28 yuan, down 3.04% from the previous trading day [1] - The opening price on the same day was 32.12 yuan, with a high of 32.16 yuan and a low of 30.01 yuan, resulting in a total trading volume of 1.246 billion yuan and a turnover rate of 6.41% [1] - Zhaoyan New Drug operates in the medical services sector, focusing on innovative drug research and development services, including drug safety evaluation and pharmacology efficacy research [1] Group 2 - During the early trading session on August 4, Zhaoyan New Drug experienced a rapid rebound, with a price increase of over 2% within 5 minutes [1] - By 9:40 AM, the stock price was reported at 31.28 yuan with a trading volume of 234 million yuan [1] - On August 4, the net outflow of main funds was 55.3549 million yuan, accounting for 0.28% of the circulating market value, with a cumulative net outflow of 338 million yuan over the past five trading days, representing 1.71% of the circulating market value [1]

Company Overview - Zhaoyan New Drug Research Center Co., Ltd. focuses on non-clinical safety evaluation services for drugs, preclinical research services, and sales of laboratory animals and related products [1] - The main products include non-clinical research services, clinical services, and experimental model supply [1] Financial Performance - For Q1 2025, the company reported revenue of 287 million yuan, a year-on-year decrease of 11.54% [1] - The net profit for the same period was 41.12 million yuan, showing a year-on-year increase of 115.11% [1] - The gross profit margin was recorded at 28.61% [1] Market Position - As of August 4, the company's stock closed at 31.28 yuan, down 3.04%, with a rolling PE ratio of 60.51 times [1] - The total market capitalization is 23.444 billion yuan [1] - In terms of industry PE ratio, the average for the medical services sector is 47.79 times, with a median of 59.03 times, placing Zhaoyan New Drug at the 30th position [1][2] Institutional Holdings - As of Q1 2025, 17 institutions hold shares in Zhaoyan New Drug, all of which are funds, with a total holding of 10.9687 million shares valued at 231 million yuan [1]

证券之星消息，8月4日医疗服务板块较上一交易日下跌0.26%，昭衍新药领跌。当日上证指数报收于 3583.31，上涨0.66%。深证成指报收于11041.56，上涨0.46%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | --- | --- | --- | --- | --- | --- | --- | | 688265 | 南模生物 | 43.73 | 20.01% | | 4.08万 | 1.66亿 | | 688621 | 阳光诺和 | 66.54 | 14.84% | | 12.60万 | 8.15亿 | | 301201 | 诚达药业 | 28.10 | 4.04% | | 10.58万 | 2.93亿 | | 688222 | 成都先导 | 24.74 | 3.82% | | 33.55万 | 7.91亿 | | 002172 | 澳洋健康 | 4.25 | 3.41% | | 70.07万 | 2.93亿 | | 688046 | 药康生物 | 16.41 | 3.01% | | 4.55万 | 7293.23万 | | ...

Core Insights - The CSI 1000 Healthcare Index has shown significant growth, with a 13.89% increase over the past month, 24.30% over the last three months, and 27.10% year-to-date [1] Group 1: Index Performance - The CSI 1000 Healthcare Index is currently at 13651.50 points [1] - The index is designed to provide a diversified investment option by selecting liquid and representative securities from each industry [1] Group 2: Index Holdings - The top ten weighted stocks in the CSI 1000 Healthcare Index include: - Borui Pharmaceutical (3.51%) - Tonghua Golden Horse (2.65%) - Zai Lab (2.51%) - Zhongsheng Pharmaceutical (1.75%) - Zhaoyan New Drug (1.70%) - Anke Biotechnology (1.66%) - Yipinhong (1.63%) - Zuoli Pharmaceutical (1.59%) - Furuide (1.39%) - Dongcheng Pharmaceutical (1.33%) [1] - The index's market distribution shows that the Shanghai Stock Exchange accounts for 55.62%, while the Shenzhen Stock Exchange accounts for 44.38% [1] Group 3: Industry Composition - The industry composition of the CSI 1000 Healthcare Index is as follows: - Chemical drugs: 36.28% - Medical devices: 19.30% - Traditional Chinese medicine: 17.00% - Biological drugs: 14.30% - Medical commerce and services: 7.16% - Pharmaceutical and biotechnology services: 5.94% [2] Group 4: Sample Adjustment - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - In special circumstances, the index may undergo temporary adjustments [2] - When a sample company is delisted, it will be removed from the index, and any mergers, acquisitions, or splits will be handled according to maintenance guidelines [2]